Lisata Therapeutics, Inc. (LSTA)
LSTA moved a median of +0.26% 30 minutes after news, and +1.39% by the close. How LSTA actually reacts to news — the realized, point-in-time move the market made, measured across 193 labeled events over the last three years with zero look-ahead.
LSTA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 156 |
| 30-min | +0.26% | 58% | 174 |
| 60-min | +0.96% | 64% | 189 |
| to close | +1.39% | 64% | 192 |
| Middle 50% of LSTA reactions | -0.15% to +2.28% |
|---|---|
| Median reaction (30-min) | +0.26% |
| Measured reactions | 193 |
Half of all Lisata Therapeutics, Inc. news events land between -0.15% and +2.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LSTA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LSTA's baseline. Nothing else.
Recent LSTA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form ARS LISATA THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.94% | -2.91% | |
| Form DEF 14A LISATA THERAPEUTICS, For: Nov 09 | SEC filing · Form DEF | SEC EDGAR | -1.94% | -2.91% | |
| Form 8-K LISATA THERAPEUTICS, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.91% | |
| Lisata Therapeutics Appoints Jeff Farrow to Board of Directors | Press release | GlobeNewswire | +0.00% | +1.91% | |
| Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors | Press release | GlobeNewswire | -0.82% | -1.64% | |
| Form PRE 14A LISATA THERAPEUTICS, For: Nov 09 | SEC filing · Form PRE | SEC EDGAR | -0.82% | -1.64% | |
| Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly | Press release | GlobeNewswire | +0.00% | -13.10% | |
| Form D LISATA THERAPEUTICS, | SEC filing · Form D | SEC EDGAR | +0.00% | -13.10% | |
| Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 | Press release | GlobeNewswire | +1.38% | +3.45% | |
| Form 8-K LISATA THERAPEUTICS, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -34.20% | -30.40% | |
| Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement | Press release | GlobeNewswire | -34.20% | -30.40% | |
| Form 10-Q LISATA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.95% | |
| Form 8-K LISATA THERAPEUTICS, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.77% | |
| Lisata Therapeutics Provides Update Following Termination of Merger Agreement | Press release | GlobeNewswire | +0.00% | +11.77% | |
| Form 8-K LISATA THERAPEUTICS, For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -5.64% | -18.14% | |
| Form 8-K LISATA THERAPEUTICS, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -0.14% | |
| Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | — | +1.45% | |
| Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. | Press release | GlobeNewswire | +0.26% | -4.75% | |
| Form 8-K LISATA THERAPEUTICS, For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +0.58% | |
| Form 8-K LISATA THERAPEUTICS, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +3.77% | |
| Form 8-K LISATA THERAPEUTICS, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +3.77% | |
| Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +2.32% | +4.97% | |
| Form 10-Q LISATA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.88% | |
| Form 8-K LISATA THERAPEUTICS, For: May 03 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | +4.04% | |
| Form 10-K/A LISATA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.56% | +0.63% | |
| Form 8-K LISATA THERAPEUTICS, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +2.27% | -9.89% | |
| Form 8-K LISATA THERAPEUTICS, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.20% | |
| Form 10-K LISATA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.40% | +0.40% | |
| Form 8-K LISATA THERAPEUTICS, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.70% | +0.80% | |
| Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. | Press release | GlobeNewswire | +0.70% | +0.80% | |
| Form 8-K LISATA THERAPEUTICS, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +3.30% | |
| Lifshitz Law PLLC Announces Investigations of Lisata Therapeutics, Inc. (Nasdaq: LSTA), RAPT Therapeutics, Inc. (Nasdaq: RAPT), Mission Produce, Inc. (Nasdaq: AVO), and Allegiant Travel Company (Nasdaq: ALGT) | Press release | ACCESS Newswire | -0.22% | +0.00% | |
| Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.00% | +0.00% | |
| Form 8-K LISATA THERAPEUTICS, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +2.70% | |
| Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide | Press release | GlobeNewswire | -0.65% | +2.70% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasda | Press release | GlobeNewswire | -0.04% | +0.08% | |
| Form 8-K LISATA THERAPEUTICS, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.00% | |
| Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer | Press release | GlobeNewswire | +0.00% | +1.00% | |
| LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders | Press release | Business Wire | +0.01% | -0.25% | |
| Form S-8 LISATA THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -0.51% | |
| Form 10-Q LISATA THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.94% | -3.29% | |
| Form 8-K LISATA THERAPEUTICS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | -3.29% | |
| Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.94% | -3.29% | |
| Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ | Press release | GlobeNewswire | +1.05% | +7.31% | |
| Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent | Press release | GlobeNewswire | -3.70% | -3.70% | |
| Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 | Press release | GlobeNewswire | +6.92% | +2.30% | |
| Form 8-K LISATA THERAPEUTICS, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +3.40% | |
| Form 8-K LISATA THERAPEUTICS, For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | +0.40% | |
| Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement | Press release | GlobeNewswire | +6.33% | +6.75% | |
| Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial | Press release | GlobeNewswire | +0.43% | +9.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LSTA section they belong to.
Where else LSTA is measured.
LSTA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lisata Therapeutics, Inc.'s median reaction calculated?
Every labeled LSTA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 193 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of LSTA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LSTA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.